Gino Bureau knows a lot about Alzheimer’s disease.

The youngest of six children, he watched two of his siblings battle, and ultimately die, from the disease.

“My oldest sister, she actually passed away with Alzheimer’s disease, and then my oldest brother also has passed away with Alzheimer’s disease. End stage. Both ended up in nursing homes and it was a long process,” said Bureau.

That’s why it didn’t come as a complete shock when he learned he too had Alzheimer’s.

“Well, being the youngest and watching what had happened, and also I worked in health care,” says Bureau, “I definitely knew, I knew when it was starting, and I worked as long as I could.”

Since his diagnosis, Bureau has hit the ground running. An avid hiker, he began participating in annual Alzheimer’s walks to raise money for a cure. He also joined clinical trials. He’s currently on his third.

“There’s not enough people that are willing to do it and I think most of it is because of lack of knowledge,” said Bureau.

Bureau, like many in the Alzheimer’s community, have been waiting for a cure. Recently, results have shown promise for the drug lecanemab.

Manufacturers Biogen and Eisai say data shows the drug decreases the rate of cognitive decline in patients.

“We’re really excited about lecanemab. We’re really feeling like it’s going to slow down the progression. We’re probably still realistically quite a ways from a cure, but we’re really getting there,” said Bureau.

More detailed results are expected in November.